Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Key Stats

• Today's Range: $31.75 to $32.61
• 50-Day Range: $29.62 to $37.43
• 52-Week Range: $29.13 to $49.83
• Volume: 662,997 shs
• Average Volume: 832,352 shs
• Market Capitalization: $1.84 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.00
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 60% of companies evaluated by MarketBeat, and ranked 450th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Enovis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.34%

Earnings Growth

Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -14.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -14.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.61% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Enovis has recently decreased by 0.76%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.61% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Enovis has recently decreased by 0.76%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.55

News Sentiment

Enovis has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Enovis this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for ENOV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENOV Stock Analysis - Frequently Asked Questions

How have ENOV shares performed this year?

Enovis' stock was trading at $43.88 at the beginning of the year. Since then, ENOV shares have decreased by 27.4% and is now trading at $31.8750.
View the best growth stocks for 2025 here.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) posted its quarterly earnings data on Thursday, May, 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The company's revenue was up 8.2% on a year-over-year basis.
Read the conference call transcript.

Who are Enovis' major shareholders?

Enovis' top institutional shareholders include T. Rowe Price Investment Management Inc. (10.87%), Vanguard Group Inc. (10.69%), DAVENPORT & Co LLC (5.38%) and Dimensional Fund Advisors LP (5.13%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enovis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/16/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 6,800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $58.00
• High Stock Price Target: $70.00
• Low Stock Price Target: $50.00
• Potential Upside/Downside: +82.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($13.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.42
• P/E Growth: N/A
• Net Income: -$33.26 million
• Net Margins: -5.95%
• Pretax Margin: -7.07%
• Return on Equity: 4.39%
• Return on Assets: 2.80%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 2.27
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $2.15 billion
• Price / Sales: 0.85
• Cash Flow: $4.65 per share
• Price / Cash Flow: 6.86
• Book Value: $62.66 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 57,123,000
• Free Float: 55,494,000
• Market Cap: $1.82 billion
• Optionable: Optionable
• Beta: 1.71